DGAP-News: M1 Kliniken AG
/ Key word(s): 9 Month figures/Expansion
M1 Kliniken AG expects the positive development to continue in the 4th quarter 2020. To date, the company is not affected by the current lock-down arrangements and treatments will continue on the basis of a comprehensive hygiene concept. The Australian centers resumed operations at the end of October after a lock-down of more than three months. The high expectations for the restart were more than exceeded. In addition, the first practice in Eastern Europe (Zagreb/Croatia) was opened at the end of October 2020. For the further expansion of the practice network, M1 Kliniken AG is closely monitoring the local pandemic developments. For the time being, no further international projects will be started and a sustained decline in the number of corona cases will be awaited. In the German market, four new locations are currently being developed in cities without M1 presence. M1 is also recruiting new doctors to further expand treatment capacities. In addition, M1 has been involved in COVID19 testing since mid-year. Between July and October 2020, more than 25,000 test samples have been taken for corporate customers. A first COVID test centre in Berlin for "walk-in testing" as a prototype for further locations in Germany was opened in early November 2020. About M1 Kliniken AG Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
04.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | M1 Kliniken AG |
Grünauer Straße 5 | |
12557 Berlin | |
Germany | |
Phone: | +49 (0)30 347 47 44 14 |
Fax: | +49 (0)30 347 47 44 17 |
E-mail: | ir@m1-kliniken.de |
Internet: | https://www.m1-kliniken.de |
ISIN: | DE000A0STSQ8 |
WKN: | A0STSQ |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart, Tradegate Exchange |
EQS News ID: | 1145081 |
End of News | DGAP News Service |
|
1145081 04.11.2020
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.